Guanfacine for ADHD: Optimal Patient and Symptom Profiles

Primary Patient Populations for Guanfacine

The American Academy of Pediatrics recommends guanfacine as a preferred agent for patients with ADHD and comorbid substance use disorders, due to its non-controlled status and lack of abuse potential 1, 2, 3
Guanfacine may reduce tics and is strongly preferred over stimulants, which can exacerbate tic symptoms, in patients with ADHD and tic disorders or Tourette's syndrome 2, 3

The American Academy of Pediatrics suggests that guanfacine can be prescribed as part of multimodal treatment for elementary school-aged children (6-11 years) with sufficient evidence, though less strong than stimulants 4
Guanfacine extended-release is approved in some countries for adult ADHD and represents an effective monotherapy option, though evidence is stronger for pediatric populations 4, 1

The American Academy of Pediatrics recommends that guanfacine can be used as adjunctive therapy to stimulants, potentially increasing treatment effects and/or decreasing stimulant-related adverse effects, particularly sleep disturbances and cardiovascular effects 2, 3
Combination therapy with guanfacine and stimulants may allow use of lower stimulant doses, potentially reducing adverse effects 1

Treatment effects with guanfacine emerge in 2-4 weeks, significantly slower than stimulants which work within hours 2
Guanfacine requires evening administration due to sedation as a common adverse effect 2

The American Academy of Pediatrics warns that premature discontinuation of guanfacine due to perceived inefficacy should be avoided, as it requires 2-4 weeks for therapeutic benefit 2
Stimulants remain first-line for severe ADHD without contraindications, and guanfacine should not be used as monotherapy when rapid symptom control is required 4, 2

The American Academy of Pediatrics approves guanfacine extended-release for children and adolescents aged 6-17 years, as a second-line treatment option, with stimulants remaining first-line 5
Guanfacine should be strongly considered as first-line therapy in specific clinical scenarios, such as disruptive behavior disorders or oppositional symptoms comorbid with ADHD, tic disorders or Tourette's syndrome, substance use disorders, sleep disturbances, and intellectual disability with ADHD 6

Initiate guanfacine extended-release at 1 mg once daily, titrating by 1 mg weekly based on response and tolerability to reach a target dose range of 0.05-0.12 mg/kg/day or 1-7 mg/day (maximum 7 mg daily), and administer in the evening due to frequent somnolence/fatigue 7, 6, 8

The effect sizes for guanfacine are in the medium range and smaller than stimulants, but this should not preclude its use when clinically indicated, with improvements in ADHD symptoms sustained over 24 months in open-label extension trials 5

Monitor for hypotension/bradycardia, cardiac conduction abnormalities, and sedation, with warnings existing regarding discontinuation effects and allergic reactions 8, 5

Guanfacine can be used as adjunctive therapy to stimulants, potentially increasing treatment effects and/or decreasing stimulant-related adverse effects, with the American Academy of Child and Adolescent Psychiatry suggesting combination therapy may be beneficial in some cases 6, 7